The "Checkpoint Inhibitor Refractory Cancer Drugs Market -- Growth, Share, Opportunities & Competitive Analysis, 2025 -- 2032" report has been added to the Credence Research Inc. offering. The global ...

The study focuses on patients unlikely to benefit from azacitidine/venetoclax or showing early resistance. ・SLS009 showed ...

Application supported by Phase 3 data reinforcing teclistamab regimens as a potential standard of care after at least one prior therapy1 Teclistamab monotherapy delivered superior progression-free ...

FACE binds to CD71 on the T‑cell surface in CAR T cell preparation, and post-infusion, the same FACE molecules attach to CD71 on leukemia cells.

CAR T-cell immunotherapy improved progression-free and overall survival in patients with relapsed or refractory marginal zone ...

In this phase 2 study, researchers aimed to evaluate the effectiveness of tyrosine kinase inhibition in relapsed or refractory germ cell tumors.

The "Checkpoint Inhibitor Refractory Cancer Drugs Market - Growth, Share, Opportunities & Competitive Analysis, 2025 - 2032" report has been added to the ...

Announced data from cohort 4 of soquelitinib atopic dermatitis Phase 1 trial demonstrating positive safety and efficacy results, including in ...

The phase 3 SUCCESSOR-2 trial shows mezigdomide-based therapy improves PFS in R/R multiple myeloma patients previously exposed to lenalidomide.

OS of 8.9 months versus 5.8 months with trifluridine/tipiracil alone, supporting phase III ...

Bristol Myers Squibb (NYSE: BMY) today announced positive interim Phase 3 results from the SUCCESSOR-2 study (NCT05552976).

Melanie Stein, ND Clinical improvement in treatment-refractory MCAS with normal conventional biomarkers and profound oral ...